Investor Presentaiton

Investor presentation Full year 2018 Slide 64 Continued value and volume growth in the Chinese insulin segments Chinese insulin market by segment Chinese total insulin value market shares DKK billion Device penetration Modern insulin penetration Novo Nordisk Penetration 10.0 CAGR value¹: 12.1% CAGR volume¹: 9.2% Sanofi 100% 70% 60% 8.0 80% Fast-acting 50% 6.0 4.0 2.0 Premix 60% 40% 30% . 40% 20% 20% Long-acting 10% 0.0 Nov 2013 0% 0% Nov Nov 2018 2013 1 CAGR for 5-year period Note: IQVIA covers around 50% of the total Chinese market (hospital data) Source: IQVIA Rolling MAT Nov, 2018 value figures changing diabetes Eli Lilly Tonghua Dongbao Gan & Lee Other Note: Only selected competitors Source: IQVIA Rolling MAT Nov, 2018 value figures 48% 18% 12% 11% 7% 4% Nov 2018 novo nordisk

View entire presentation